GlaxoSmithKline, the British pharmaceutical group, saw its share price rise strongly after winning US approval for a controversial diabetes drug.
The Food and Drug Administration in the United States has overwhelmingly voted to preserve the availability of GSK's Avandia diabetes drug in the United States following flagged health concerns.
In May, the New England Journal of Medicine published a study that showed Avandia increased the risk of heart attacks by 43%.
GlaxoSmithKline says the findings are inaccurate, but last week noted that sales of Avandia dropped by 22% to £349m during the second quarter of 2007.
In London this afternoon GSK had jumped by 3.29% to 1,255 pence.
